The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit Podcast 208 – Felipe Teran on Why We are Doing CPR Wrong - September 18, 2017
- EMCrit 207 – A Case to Acid Test your Resus Logistics - September 5, 2017
- EMCrit Wee – Central Line MicroSkills – Dilation - August 29, 2017